Literature DB >> 25601897

Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative.

Abdulelah Alshaiban1, Vandhana Muralidharan-Chari1, Anne Nepo2, Shaker A Mousa3.   

Abstract

Abnormal cellular adhesion is one of the primary causes of vaso-occlusive crisis in sickle cell disease (SCD). Levels of intercellular adhesion molecule 1 (ICAM-1) and P-selectin are upregulated, resulting in increased adhesion of leukocytes and sickle red blood cells (RBCs) to endothelium. This study compares the inhibitory effect of a sulfated nonanticoagulant heparin (S-NACH) derivative with a low-molecular-weight heparin, tinzaparin, on the adhesion of sickle RBCs to endothelium. The S-NACH exhibits minimum effects on hemostasis and bleeding and interferes with the binding of pancreatic cancer cells to endothelial cells via P-selectin. We show by static binding assay that pretreatment of both erythrocytes and endothelial cells with S-NACH significantly inhibits the increased adhesion of sickle RBCs to endothelial cells. The S-NACH treatment also decreases the higher plasma levels of (adhesion biomarkers) ICAM-1 and P-selectin in SCD mice. This investigation signals further research into the potential use of S-NACH in treating vaso-occlusions with minimal bleeding events in patients with SCD.
© The Author(s) 2015.

Entities:  

Keywords:  ICAM-1; adhesion molecules; endothelial cells; heparin; selectin; sickle cell disease; sickle red blood cells; sulfated nonanticoagulant heparin; tinzaparin

Mesh:

Substances:

Year:  2015        PMID: 25601897     DOI: 10.1177/1076029614565880

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  10 in total

1.  Developing new pharmacotherapeutic approaches to treating sickle-cell disease.

Authors:  Marilyn J Telen
Journal:  ISBT Sci Ser       Date:  2016-11-15

2.  Hypoxia-enhanced adhesion of red blood cells in microscale flow.

Authors:  Myeongseop Kim; Yunus Alapan; Anima Adhikari; Jane A Little; Umut A Gurkan
Journal:  Microcirculation       Date:  2017-07       Impact factor: 2.628

Review 3.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

Review 4.  Borrelia burgdorferi glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease.

Authors:  Yi-Pin Lin; Lingyun Li; Fuming Zhang; Robert J Linhardt
Journal:  Microbiology       Date:  2017-11-08       Impact factor: 2.777

Review 5.  Therapeutic strategies for sickle cell disease: towards a multi-agent approach.

Authors:  Marilyn J Telen; Punam Malik; Gregory M Vercellotti
Journal:  Nat Rev Drug Discov       Date:  2019-02       Impact factor: 84.694

6.  Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.

Authors:  Jeremy P Wood; Lisa M Baumann Kreuziger; Umesh R Desai; Alan E Mast
Journal:  Br J Haematol       Date:  2016-06-15       Impact factor: 6.998

7.  Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway.

Authors:  Mohamed A Ghonim; Jeffrey Wang; Salome V Ibba; Hanh H Luu; Kusma Pyakurel; Ilyes Benslimane; Shaker Mousa; A Hamid Boulares
Journal:  J Transl Med       Date:  2018-09-01       Impact factor: 5.531

8.  Red blood cell phenotype fidelity following glycerol cryopreservation optimized for research purposes.

Authors:  Stephen C Rogers; Laura B Dosier; Timothy J McMahon; Hongmei Zhu; David Timm; Hengtao Zhang; Joseph Herbert; Jacqueline Atallah; Gregory M Palmer; Asa Cook; Melanie Ernst; Jaya Prakash; Mark Terng; Parhom Towfighi; Reid Doctor; Ahmed Said; Matthew S Joens; James A J Fitzpatrick; Gabi Hanna; Xue Lin; Julie A Reisz; Travis Nemkov; Angelo D'Alessandro; Allan Doctor
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

9.  Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.

Authors:  Yunus Alapan; Ceonne Kim; Anima Adhikari; Kayla E Gray; Evren Gurkan-Cavusoglu; Jane A Little; Umut A Gurkan
Journal:  Transl Res       Date:  2016-03-19       Impact factor: 7.012

10.  Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.

Authors:  Osheiza Abdulmalik; Noureldien H E Darwish; Vandhana Muralidharan-Chari; Maii Abu Taleb; Shaker A Mousa
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.